FDAnews Announces — The FDA Under a New Commissioner Webinar, May 17, 2017

Share Article

New leadership is coming to the FDA, and every FDA-regulated executive wants to know how it will affect them. Mark the calendar for Wednesday, May 17 and a webinar with a deep dive into the future of drug and device regulation, featuring three speakers who know the FDA inside and out.

The FDA Under a New Commissioner
**An FDAnews Webinar**
May 17, 2017 — 1:30 p.m. – 3:00 p.m. ET
http://www.fdanews.com/newcommissioner                
It’s Donald Trump’s FDA now. How will that affect manufacturers?

With former FDAer Scott Gottlieb at the helm, will the agency:

  • Relax NDA and NDD standards or toughen them?
  • Spark more frequent inspections or go a little easier?
  • Speed up issuance of new regulations or slow the process down?
  • Enhance patient safety or threaten it?

Mark the calendar for Wednesday, May 17, when three leading FDA analysts divine the future for every FDA-regulated business:

  • Wayne Pines was the FDA’s chief media spokesman for seven years. He has authored or edited a dozen books about crisis communication and the FDA, and was named the FDA Alumnus of the Year in 2004. He now manages crisis communications for FDA-regulated clients as a senior consultant with Apco Worldwide.
  • Peter Pitts worked directly with Scott Gottlieb while at the FDA. Mr. Pitts was senior communications and policy adviser to the FDA Commissioner, and associate commissioner for external relations supervising the offices of public affairs, special health issues, executive secretariat and ombudsman and the advisory committee on oversight and management. He co-founded and is now president of the Center for Medicine in the Public Interest.
  • Marc Sheineson was the associate commissioner for legislative affairs of the FDA where he was involved in many agency innovations, including prescription drug user fees, debarment, medical device amendments and nutritional labeling. He was also counsel to the ranking member of the Health Subcommittee of the House of Representatives Committee on Ways and Means.

Attendees will discover Trump-Gottlieb administration priorities, both announced and unannounced ... learn what changes manufacturers must make starting now to achieve goals for 2017 and beyond ... get advance warning of day-to-day changes likely to take place at the agency ... and come away with specific, practical guidance based on Commissioner Gottlieb’s present and past positions.

For drugs, biologics, devices, clinical trials or another FDA-regulated industry, change is a certainty. The Trump-Gottlieb FDA will shape business for years to come. Don’t get caught short. Gain the insights before the changes start rolling out.

Webinar Details:
The FDA Under a New Commissioner
**An FDAnews Webinar**
May 17, 2017 — 1:30 p.m. – 3:00 p.m. ET
http://www.fdanews.com/newcommissioner                    

Tuition:
$287 per site

Easy Ways to Register:
Online:     http://www.fdanews.com/newcommissioner                                                                
By phone: 888-838-5578 or 703-538-7600

About FDAnews:
FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews' print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA's complex and ever-changing regulations.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michelle Butler
FDANEWS
+1 (703) 538-7665
Email >
FDAnews
Like >
Visit website